ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 1 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $13,700,980 | -28.9% | 683,000 | 0.0% | 0.00% | -25.0% |
Q2 2023 | $19,267,430 | +64.0% | 683,000 | 0.0% | 0.00% | +100.0% |
Q1 2023 | $11,747,600 | -14.6% | 683,000 | 0.0% | 0.00% | -33.3% |
Q4 2022 | $13,755,620 | -7.0% | 683,000 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $14,794,000 | -22.9% | 683,000 | 0.0% | 0.00% | -25.0% |
Q2 2022 | $19,192,000 | -39.1% | 683,000 | 0.0% | 0.00% | -20.0% |
Q1 2022 | $31,514,000 | -45.1% | 683,000 | 0.0% | 0.01% | -44.4% |
Q4 2021 | $57,413,000 | +26.1% | 683,000 | 0.0% | 0.01% | +12.5% |
Q3 2021 | $45,515,000 | +27.7% | 683,000 | +1.9% | 0.01% | +33.3% |
Q2 2021 | $35,644,000 | +122.0% | 670,000 | +81.1% | 0.01% | +100.0% |
Q1 2021 | $16,054,000 | -63.6% | 370,000 | -56.5% | 0.00% | -66.7% |
Q4 2020 | $44,149,000 | +103.4% | 850,000 | +28.0% | 0.01% | +80.0% |
Q3 2020 | $21,706,000 | +0.4% | 664,000 | +47.6% | 0.01% | 0.0% |
Q2 2020 | $21,609,000 | – | 450,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Decheng Capital Management III (Cayman), LLC | 2,099,583 | $42,117,635 | 14.06% |
Mayo Clinic | 187,143 | $3,754,089 | 7.23% |
Matrix Capital Management Company, LP | 13,959,973 | $280,037,058 | 3.36% |
5AM Venture Management, LLC | 490,000 | $9,829,400 | 2.83% |
Eventide Asset Management | 7,814,039 | $156,749,622 | 2.82% |
TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 961,486 | $19,287,410 | 2.70% |
Avidity Partners Management LP | 2,100,000 | $42,126,000 | 1.70% |
First Light Asset Management, LLC | 848,477 | $17,020,449 | 1.62% |
Sofinnova Investments, Inc. | 1,211,641 | $24,305,518 | 1.53% |
SECTORAL ASSET MANAGEMENT INC | 386,525 | $7,753,692 | 1.51% |